IGM Biosciences stock surges as Biogen's deal for HI-Bio is seen as a positive

Shares of IGM Biosciences Inc . (NASDAQ:) surged 38% Wednesday after BIIB announced the acquisition of HI-Bio, which is seen as a positive for IGMS.

BIIB announced the acquisition of HI-Bio. Its lead asset felzartamab, a CD38 targeting antibody, is being developed for numerous kidney autoimmune/inflammatory diseases.

Reacting to the news, analysts at RBC highlighted the positives for IGMS, noting the company “recently pivoted both imvotamab (CD20xCD3) and ‘2664 (CD38xCD3) into the I&I space.”

“BIIB’s acquisition of HI-Bio and its CD38 antibody for I&I provides another vote of confidence in non-CAR-T cell B-cell depleting approaches, with IGMS moving both CD20xCD3 and CD38xCD3 assets forward,” said analysts at RBC.

“With the current valuation nearing the company’s cash level, we believe its I&I potential is widely underappreciated, and efficacy signals from imvotamab end-’24/early-’25 and/or ‘2644 in solid tumors early 2025 can lead to substantial stock upside,” concluded the bank.


This website uses cookies. By continuing to use this site, you accept our use of cookies.